GlassScriptPhysician profile
Michael J Neshewat
NPI 1174553770
$13,420.93
in general payments reported to CMS, 2019-2025
56 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $940 · 2021: $2,054 · 2022: $2,061 · 2023: $2,345 · 2024: $2,741 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,467.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,412.56 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $2,037.03 | 2021-2025 | |
| Lilly USA, LLC | $865.40 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $671.93 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $532.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $517.10 | 2021-2025 | Rexulti |
| Pfizer INC. | $514.46 | 2019-2025 | |
| Astellas Pharma US INC | $453.78 | 2019-2025 | Veozah |
| Shionogi INC | $422.40 | 2023-2025 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $382.47 | 2020-2025 | Farxiga, Breztri, Flumist Quadrivalent |
| Aimmune Therapeutics, INC. | $376.09 | 2023-2025 | Vowst, Zenpep |
| Novartis Pharmaceuticals Corporation | $333.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.49 | 2020-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $293.37 | 2021-2025 | Caplyta |
| Allergan, INC. | $240.64 | 2019-2020 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Neshewat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.